This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed Review

Biology of RANK, RANKL, and osteoprotegerin

Brendan F Boyce* and Lianping Xing

Arthritis Research & Therapy 2007, 9(Suppl 1):S1 doi:10.1186/ar2165

Accesses  

  • Last 30 days: 181 accesses
  • Last 365 days: 2016 accesses
  • All time: 14224 accesses

Cited by

BioMed Central: 3 citations

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations